Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Fujian Shengdi Pharmaceutical Co · Phase 2 · Active, not recruiting · Enrollment 264

NCT07458269

ArmPopulationDoseWeeksEstimandWeight change
Ribupatide: Dose 1Obesity or overweightn/rn/rn/rn/r
Ribupatide: Dose 2Obesity or overweightn/rn/rn/rn/r
Ribupatide: Dose 3Obesity or overweightn/rn/rn/rn/r
Ribupatide: Dose 4Obesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r